Investor Presentaiton
Appendix 6: History of AFT Pharmaceuticals
AFT was founded 23 years ago by Dr Hartley and Marree Atkinson. Since then AFT has remained an Atkinson-family controlled
business and has grown organically into Australia and internationally
The 2015 IPO raised funds to pursue a more aggressive (and loss-making) R&D-led growth strategy. AFT has now returned to
profitability as intended, as the company was prior to IPO
Development of
Maxigesic
commences
Maxigesic registered
in New Zealand and
sales commence
AFT launches the sale
of products into the
SE Asian market
AFT returns to
profitability following a
significant investment
period funded by the
2015 IPO
AFT completes licensing
Maxigesic IV to Hikma
for USA
FDA accepts Maxigesic
IV Registration
1997
2004
2005
2009
2013
2014
2015
2019
2020
2021
AFT founded by Dr
Hartley and Marree
Atkinson
First sales into
Australia
AFTpharmaceuticals
Maxigesic
registered in
Australia
Maxigesic sales
commence in
Australia
$33m IPO to fund
new R&D
development
programmes for
Maxigesic and other
proprietary products
In FY20 AFT delivers
over $100m of
revenue and
operating profit
growth of 87%
Page 26View entire presentation